$1.73
1.76% (Daily)
Market Cap
$109.44M
Revenue
$127.63M
Rank by MCap
#1333
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James Karrels
Headquarters
Rockville, MD
Employees
341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which...
Loading chart…